Roquefort Investments PLC (ROQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roquefort Investments PLC (ROQ) has a cash flow conversion efficiency ratio of -0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-329.55K ≈ $-40.10 USD) by net assets (GBX4.75 Million ≈ $578.29 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Roquefort Investments PLC fund operations to measure how many days the company can operate on defensive assets alone.
Roquefort Investments PLC - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Roquefort Investments PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Roquefort Investments PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roquefort Investments PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Itaconix plc
LSE:ITX
|
-0.059x |
|
Adventure Box Technology AB
ST:ADVBOX
|
0.624x |
|
Sprott Physical Uranium Trust
TO:U-U
|
0.000x |
|
ATMOFIZER TECHNOL.INC. B
F:J3KA
|
-0.019x |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
0.024x |
|
Bumhan Fuel Cell Co. Ltd.
KQ:382900
|
N/A |
|
SysGroup PLC
LSE:SYS
|
-0.014x |
|
ICG Longbow Senior Secured UK Property Debt Investments Ltd
LSE:LBOW
|
0.036x |
Annual Cash Flow Conversion Efficiency for Roquefort Investments PLC (2021–2024)
The table below shows the annual cash flow conversion efficiency of Roquefort Investments PLC from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see ROQ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX4.89 Million ≈ $594.85 |
GBX-783.73K ≈ $-95.36 |
-0.160x | +49.14% |
| 2023-12-31 | GBX5.50 Million ≈ $669.14 |
GBX-1.73 Million ≈ $-210.92 |
-0.315x | -44.00% |
| 2022-12-31 | GBX7.21 Million ≈ $876.84 |
GBX-1.58 Million ≈ $-191.93 |
-0.219x | +65.93% |
| 2021-12-31 | GBX4.08 Million ≈ $496.74 |
GBX-2.62 Million ≈ $-319.15 |
-0.642x | -- |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more